Výsledky vyhledávání

Akademický článek

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)

Background This phase 1 study evaluated PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in two clinical states of prostate cancer (PC), metastatic castration-resistant PC (mCRPC) and biochemical recurrence (BCR).Methods For dose escal

Externí odkaz: https://doaj.org/article/a4a8a3a078ab4567a1641ae4c2b5d1db

Zobrazit plný text záznamu

Exact simultaneous confidence intervals for logical selection of a biomarker cut‐point

Autor: Yang Han, Szu-Yu Tang, Jason C. Hsu, Hui-Min Lin

Publikováno v: Han, Y, Tang, S-Y, Lin, H-M & Hsu, J C 2021, ' Exact simultaneous confidence intervals for logical selection of a biomarker cut-point ', Biometrical Journal, pp. 1-18 . https://doi.org/10.1002/bimj.202000159

This article proposes four new principles for logical biomarker cut-point selection methods to adhere to: subgroup sensibility, sensitivity, specificity, and target monotonicity. At every cut-point value, our method gives confidence intervals not onl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d662571311710e3125f9c346dd7e77c
https://doi.org/10.1002/bimj.202000159

Zobrazit plný text záznamu

737 Inhibition of P21-activated kinase 4 (PAK4) reverts immune exclusion and restores anti-tumor immunity in the tumor microenvironment

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

BackgroundP21-activated kinase 4 (PAK4) is a serine/threonine protein kinase that is mostly expressed in tumor and stroma cells. PAK4 activates tumor WNT/β-catenin pathway and regulates cellular morphology, motility, EMT, cell proliferation and surv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb992a17f4468fd8accc364f85e3ea0e
https://doaj.org/article/f1d6517467594e24b8981f644a3baeab

Zobrazit plný text záznamu

Multiple Testing

Autor: Yi Liu, Jason Hsu, Szu-Yu Tang

Publikováno v: Handbook of Statistical Methods for Randomized Controlled Trials ISBN: 9781315119694

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4004aab691c883fb3da248f99523912a
https://doi.org/10.1201/9781315119694-18

Zobrazit plný text záznamu

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

Publikováno v: Applied Immunohistochemistry & Molecular Morphology

Supplemental Digital Content is available in the text.
Cancer immunotherapies, such as atezolizumab, are proving to be a valuable therapeutic strategy across indications, including non–small cell lung cancer (NSCLC) and urothelial cancer (UC).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f0543f0a044919d6864d7831524e5f6
http://europepmc.org/articles/PMC6369970

Zobrazit plný text záznamu

Challenges of Bridging Studies in Biomarker Driven Clinical Trials: The Impact of Companion Diagnostic Device Performance on Clinical Efficacy

Autor: Bonnie LaFleur, Szu-Yu Tang

Publikováno v: Springer Proceedings in Mathematics & Statistics ISBN: 9783319673851

Personalized medicine involves the co-development of both the therapeutic agent (Rx) and a companion diagnostic device (CDx), which directs a group of patients to a particular treatment. There are instances, however, when there are competing, or mult

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0929fe32c22c0f032f9f1c581b848987
https://doi.org/10.1007/978-3-319-67386-8_16

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání